Stockwinners Market Radar for January 07, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:08 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Safety checks on some Boeing (BA) jets hit a snag over paperwork on Sunday, as U.S. authorities searched for a missing panel that blew off a new Boeing 737 MAX 9 jet in midair on Friday, Reuters' David Shepardson, Valerie Insinna and Tim Hepher report. The Federal Aviation Administration on Saturday ordered the temporary grounding of 171 Boeing jets installed with the same panel after the eight-week-old Alaska Airlines (ALK) jet was forced to make an emergency landing with a gap in the fuselage, the authors note. "They will remain grounded until the FAA is satisfied that they are safe," the agency said in a statement on Sunday. 2. Some executives and board members at Elon Musk's companies fear the Tesla (TSLA) and SpaceX chief executive's drug use could have major consequences not just for his health, but also the six companies and billions in assets he oversees, The Wall Street Journal's Emily Glazer and Kirsten Grind report, citing people familiar with the matter. The world's wealthiest person has used LSD, cocaine, ecstasy and psychedelic mushrooms, often at private parties around the world, where attendees sign nondisclosure agreements or give up their phones to enter, according to people who have witnessed his drug use and others with knowledge of it. Illegal drug use would likely be a violation of federal policies that could jeopardize SpaceX's billions of dollars in government contracts, the authors add. 3. Disney (DIS) is caught in a contentious battle with multiple activist investors. Shareholders should come out ahead no matter who the winner is, Carleton English writes in this week's edition of Barron's. There's likely to be even more mudslinging over the next few months. Proxy fights, especially ones with multiple actors, are expensive and can be distracting to management. But in this case, it may be just what Disney needs, the author says. Change should keep coming, whether it's board refreshment, improved succession planning, or tying executive pay to financial performance, as Trian has demanded. And that should be good news, regardless of which path Disney follows, the publication adds. 4. Warner Bros.' (WBD) "Wonka" stayed atop the domestic box office with another $14.4M from a little over 3,800 theaters. Overseas, the Timothee Chalamet-led movie crossed the $300M mark for a global tally of $465.8M. The musical was the biggest winner of the Christmas season and the best showing of any year-end holiday title. 5. Abercrombie & Fitch (ANF), Medtronic (MDT), Comcast (CMCSA), Atlanta Braves (BATRA), IAC (IAC), and Interactive Brokers (IBKR) saw positive mentions in this week's edition of Barron's.

15:16 EST Vincerx announces results from Phase 1 NIH-sponsored combo study of enitociclib - Vincerx Pharma announced clinical results from a Phase 1 NIH-sponsored study of enitociclib in combination with venetoclax and prednisone for the treatment of relapsed/refractory lymphoma. "Enitociclib continues to differentiate itself in the CDK9 inhibitor field," said Ahmed Hamdy, Chief Executive Officer of Vincerx. "Enitociclib is well tolerated, making it 'the partner of choice' for novel combinations. We are pleased to see the high response rate and tolerability of enitociclib in combination with venetoclax and prednisone in patients with hard-to-treat types of non-Hodgkin's lymphoma such as peripheral T-cell lymphoma and double-hit diffuse large B-cell lymphoma. Previous reports of venetoclax monotherapy in PTCL show low response rates; thus, we believe we are seeing compelling evidence for synergism between enitociclib and venetoclax in this patient population." Hamdy continued, "In addition to the exciting results with enitociclib, VIP236 and VIP943, the lead drugs from our cutting-edge VersAptx platform, are rapidly progressing through dose-escalation studies. To date, 15 patients with relapsed/refractory advanced or metastatic solid tumors have been treated with VIP236, and we are observing a promising safety profile and preliminary evidence of clinical activity with once every 3-week dosing. Enrollment in the second cohort of the VIP943 trial is nearly complete. Preliminary pharmacokinetic results from the first cohort of our VIP943 antibody drug conjugate trial show very little free payload in circulation, consistent with the favorable safety profile observed to date. ADCs and bi-specifics have been limited by numerous safety and efficacy challenges, so the profile we are observing in these initial dose levels is exciting."

14:00 EST Qiagen announces plans to return approximately $300M to shareholders - Qiagen announced a plan to return up to approximately $300M to shareholders through a synthetic share repurchase that combines a direct capital repayment with a reverse stock split. Qiagen has decided to implement the maximum $300M value of the mandate given at the Annual General Meeting in June 2023, where shareholders gave virtually unanimous approval for the related resolutions. This approach is designed to return cash to shareholders in a more efficient way than through a traditional open-market repurchase program. It would also enhance earnings per share through the reduction in outstanding shares.

09:03 EST Akoya Biosciences, Thermo Fisher announce license/distribution agreement - Akoya Biosciences (AKYA) announced that it has entered into a license and distribution agreement with Thermo Fisher Scientific (TMO). The agreement enables Akoya to market the combination of Akoya's spatial biology solutions, including its PhenoImager systems and PhenoCode reagents with the Thermo Fisher ViewRNA In Situ Hybridization Assays, for detection of protein and RNA biomarkers in tissue samples. The agreement facilitates a streamlined workflow for whole-slide, multiomic imaging, where protein and RNA biomarkers play complementary roles in defining cell phenotypes and cell states, respectively, in a tissue sample. Measuring both protein and RNA analytes provides researchers with a more comprehensive understanding of tumor progression, molecules and biologics, enabling development of more accurate biomarker signatures. The Thermo Fisher ViewRNA assays are compatible with Akoya's PhenoCode protein panels, which deliver industry-leading solutions for high-plex and high-throughput spatial proteomics. The aim is to offer a comprehensive suite of ready-to-use and customizable multiomic solutions, streamlining the progression of biomarker programs from discovery to diagnostics.